By Nadine A Yehya – UCDavis Health –
Funding promotes local production of CAR T-cell immunotherapy for cancer patients
UC Davis Health’s Stem Cell Program has received a $500,000 grant from California health insurer Health Net to improve cancer patients’ access to life-saving CAR T therapies and clinical trials. CAR (chimeric antigen receptor) T-cell therapy is a form of immunotherapy that reprograms the immune cells to better target diseases such as cancer.
